STEAP1 and prostate neoplasm: Based on a high expression level of STEAP1, Yuan et al. (2019) established a novel contrast agent for ultrasound imaging by conjugating biotinylated STEAP1 monoclonal antibodies with streptavidin-coated SonoVue microbubbles, providing a prospective method to identify prostate tumors effectively in vivo.